Literature DB >> 18612998

A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation.

Olivia I Okereke1, Dennis J Selkoe, Michael N Pollak, Meir J Stampfer, Frank B Hu, Susan E Hankinson, Francine Grodstein.   

Abstract

OBJECTIVE: Insulin degradation pathways may be related to Alzheimer's disease pathology. In preliminary analyses, we considered the relation of combined lower insulin secretion (c-peptide) and higher insulin--possibly a phenotype for impaired insulin degradation--to cognitive decline.
METHOD: Fasting plasma c-peptide and insulin were measured in 1,187 non-diabetic Nurses' Health Study participants (mean age = 64 years). Cognitive testing began 10 years later. Participants completed three repeated assessments (over an average span of 4.4 years) of verbal memory, a strong predictor of Alzheimer disease development. C-peptide and insulin distributions were dichotomized at their medians to create four cross-tabulated categories. Multivariable linear mixed effects models were used to relate c-peptide/insulin categories to cognitive decline.
RESULTS: Compared to the lower c-peptide/lower insulin group, women with lower c-peptide/higher insulin had a significantly faster rate of verbal memory decline: the mean difference was -0.05 units/year (95% CI -0.09,-0.01). This mean difference was similar to that which we found for women 5 years apart in age, indicating that having a profile of lower c-peptide/higher insulin appeared cognitively equivalent to aging by five years on tests of verbal memory. For women with higher c-peptide/higher insulin, the estimated mean difference in decline compared to those in the lower c-peptide/lower insulin group was statistically significant, but slightly lower, at -0.04 units/year (95% CI: -0.07,-0.02).
CONCLUSION: These preliminary analyses of a possible phenotype of impaired insulin degradation provide supportive evidence that deficits in insulin degradation may be related to late-life verbal memory decline. (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18612998      PMCID: PMC2631087          DOI: 10.1002/gps.2089

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  21 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.

Authors:  D L Horwitz; J I Starr; M E Mako; W G Blackard; A H Rubenstein
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

3.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

Review 4.  C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations.

Authors:  K S Polonsky; A H Rubenstein
Journal:  Diabetes       Date:  1984-05       Impact factor: 9.461

5.  Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease.

Authors:  M Albert; L A Smith; P A Scherr; J O Taylor; D A Evans; H H Funkenstein
Journal:  Int J Neurosci       Date:  1991-04       Impact factor: 2.292

6.  Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man.

Authors:  J H Henriksen; B Tronier; J B Bülow
Journal:  Metabolism       Date:  1987-05       Impact factor: 8.694

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

Authors:  Wesley Farris; Stefan Mansourian; Yang Chang; Loren Lindsley; Elizabeth A Eckman; Matthew P Frosch; Christopher B Eckman; Rudolph E Tanzi; Dennis J Selkoe; Suzanne Guenette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-12       Impact factor: 11.205

9.  Insulin uptake by the human alcoholic cirrhotic liver.

Authors:  A Nygren; N Adner; L Sundblad; K L Wiechel
Journal:  Metabolism       Date:  1985-01       Impact factor: 8.694

10.  Characterization of seven C-peptide antisera.

Authors:  O K Faber; C Binder; J Markussen; L G Heding; V K Naithani; H Kuzuya; P Blix; D L Horwitz; A H Rubenstein
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

View more
  7 in total

1.  Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues.

Authors:  Sid E O'Bryant; Guanghua Xiao; Fan Zhang; Melissa Edwards; Dwight C German; Xiangling Yin; Tori Como; Joan Reisch; Ryan M Huebinger; Neill Graff-Radford; Dennis Dickson; Robert Barber; James Hall; Padraig O'Suilleabhain; Paula Grammas
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  A blood-based algorithm for the detection of Alzheimer's disease.

Authors:  Sid E O'Bryant; Guanghua Xiao; Robert Barber; Joan Reisch; James Hall; C Munro Cullum; Rachelle Doody; Thomas Fairchild; Perrie Adams; Kirk Wilhelmsen; Ramon Diaz-Arrastia
Journal:  Dement Geriatr Cogn Disord       Date:  2011-08-24       Impact factor: 2.959

3.  IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive function in older adults.

Authors:  G Peggy McFall; Sandra A Wiebe; David Vergote; David Westaway; Jack Jhamandas; Roger A Dixon
Journal:  Neurobiol Aging       Date:  2013-04-16       Impact factor: 4.673

Review 4.  Drug repositioning for Alzheimer's disease.

Authors:  Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

5.  Insulin and sex interactions in older adults with mild cognitive impairment.

Authors:  Brenna Cholerton; Laura D Baker; Emily H Trittschuh; Paul K Crane; Eric B Larson; Matthew Arbuckle; Hector Hernandez Saucedo; Susan M McCurry; James D Bowen; Wayne C McCormick; Suzanne Craft
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 6.  Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.

Authors:  Christian Hölscher
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 6.497

7.  Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).

Authors:  Grazia Daniela Femminella; Eleni Frangou; Sharon B Love; Gail Busza; Clive Holmes; Craig Ritchie; Robert Lawrence; Brady McFarlane; George Tadros; Basil H Ridha; Carol Bannister; Zuzana Walker; Hilary Archer; Elizabeth Coulthard; Ben R Underwood; Aparna Prasanna; Paul Koranteng; Salman Karim; Kehinde Junaid; Bernadette McGuinness; Ramin Nilforooshan; Ajay Macharouthu; Andrew Donaldson; Simon Thacker; Gregor Russell; Naghma Malik; Vandana Mate; Lucy Knight; Sajeev Kshemendran; John Harrison; Christian Hölscher; David J Brooks; Anthony Peter Passmore; Clive Ballard; Paul Edison
Journal:  Trials       Date:  2019-04-03       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.